Hydrocortisone versus vasopressin for the management of adult patients with septic shock refractory to norepinephrine: A multicenter retrospective study
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2023
DOI: 10.1002/phar.2811 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2023. Verfasst von Steven Kulesza und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Ascension St. John Hospital, Detroit, Michigan, USA. Hauptthemen laut MEDLINE: Norepinephrine, Shock, Septic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Themen: Sepsis
Abstract (Originalsprache)
Study Objective Significant practice variation exists when selecting between hydrocortisone and vasopressin as second line agents in patients with septic shock in need of escalating doses of norepinephrine. The goal of this study was to assess differences in clinical outcomes between these two agents.
Design
Multicenter, retrospective, observational study.
Setting
Ten Ascension Health hospitals. Patients Adult patients with presumed septic shock receiving norepinephrine prior to study drug initiation between December 2015 and August 2021.
Intervention
Vasopressin (0.03–0.04 units/min) or hydrocortisone (200–300 mg/day). Measurements and Main Results A total of 768 patients were included with a median (interquartile range) SOFA score of 10 (8–13), norepinephrine dose of 0.3 mcg/kg/min (0.1–0.5 mcg/kg/min), and lactate of 3.8 mmol/L (2.4–7.0 mmol/L) at initiation of the study drug. A significant difference in 28‐day mortality was noted favoring hydrocortisone as an adjunct to norepinephrine after controlling for potential confounding factors (OR 0.46 [95% CI, 0.32–0.66]); similar results were seen following propensity score matching. Compared to vasopressin, hydrocortisone initiation was also associated with a higher rate of hemodynamic responsiveness (91.9% vs. 68.2%, p < 0.01), improved resolution of shock (68.8% vs. 31.5%, p < 0.01), and reduced recurrence of shock within 72 h (8.7% vs. 20.7%, p < 0.01).
Conclusions
Addition of hydrocortisone to norepinephrine was associated with a lower 28‐day mortality in patients with septic shock, compared to the addition of vasopressin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Ascension St. John Hospital, Detroit, Michigan, USA.
- Department of Pharmacy, Ascension St Vincent's Riverside Hospital, Jacksonville, Florida, USA.
- Department of Pharmacy, Ascension St Vincent's Birmingham Hospital, Birmingham, Alabama, USA.
- Department of Pharmacy, Ascension Genesys Hospital, Grand Blanc, Michigan, USA.
- Eugene Applebaum College of Pharmacy & Health Sciences, Wayne State University, Detroit, Michigan, USA.
ORCID-Profile: Bryan Allen, Stephanie B Edwin
Zitieren
APA
Kulesza, S., Gignac, L., Colvin, C. A., Boll, S., Giuliano, C., Haan, B., Allen, B., Perez, M. M., Allen, M., & Edwin, S. B. (2023). Hydrocortisone versus vasopressin for the management of adult patients with septic shock refractory to norepinephrine: A multicenter retrospective study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.2811
Vancouver
Kulesza S, Gignac L, Colvin CA, Boll S, Giuliano C, Haan B, et al. Hydrocortisone versus vasopressin for the management of adult patients with septic shock refractory to norepinephrine: A multicenter retrospective study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023. doi:10.1002/phar.2811
BibTeX
@article{Kulesza2023,
author = {Kulesza, Steven and Gignac, Lindsey and Colvin, C Allis and Boll, Skyler and Giuliano, Christopher and Haan, Bradley and Allen, Bryan and Perez, Mary M and Allen, Monica and Edwin, Stephanie B},
title = {Hydrocortisone versus vasopressin for the management of adult patients with septic shock refractory to norepinephrine: A multicenter retrospective study},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2023},
doi = {10.1002/phar.2811}
}
EUVIMED